7 Things About the Path to Profitability Your Boss Wants You to Know | Diaceutics

7 Things About the Path to Profitability Your Boss Wants You to Know

May 13th, 2016


Companion diagnostic services and personalized medicine are quickly revolutionizing the way that drugs are researched, created and marketed. To be prepared for these changes, it’s vital to understand the trends at work in the industry: Here’s what you need to know.

1. Applicability – and Demand – are Growing Quickly
Personal and companion diagnostic services have seen a rapid rise in popularity, starting in the early 2010s, and this is expected to continue. Part of the reason is awareness: physicians and consumers are becoming familiar with personalized medicine and unique diagnostic options and this has led to more market activity. Another important factor is applicability, especially in the testing market, where an increasing number of genetic tests in new disease areas have become available.

2. Decision-Based Applications are Also on the Rise
Decision-based applications help patients and physicians make choices. Today’s personalized tests and monitoring can provide valuable information when it comes to analyzing the chances of a treatment’s success or necessity. When marketing related products and services, it’s smart to focus on decision-making and the value of informed knowledge.

3. Physicians are Responsible for an Increasing Rise in Demand
While consumers are primarily attracted by the new information made available by such personalized testing, physicians often have another reason for encouraging these applications – smarter decisions. The latest work in this area allows doctors to make more immediate and accurate recommendations regarding drug treatments and alternative procedures in areas from oncology to companion devices for in vitro work. More information leads to better informed choices and happier patients…so don’t be surprised when doctors ask about these sorts of applications.

4. Consumers Are Primarily Interested in Predictive Testing
While physicians may be asking for more data to help prescribe the right therapy, individual consumers are more likely to notice predictive testing options. These are genetic tests and similar services that assess the risk of specific diseases. Such services are particularly useful for those who have certain hereditary health concerns in their family and want more information regarding their own personal susceptibility.

5. Pharma Companies are Already Investing…
A major roadblock to the development of personalized medicine has traditionally been lack of interest. Pharmaceutical companies have far better profit margins with drugs than with personalized tests or treatments. However, due to increased demand around testing this has begun to change. Evidence for this comes in the deal between Aveo and Biodesix for a $15 million research project on diagnostics. The deal splits the profits between both companies and provides a template for other ventures to follow.

6. …Because Drug Development is Changing
An important result for these new deals is that drug development is evolving. Data is becoming increasingly important and diagnostic services can help today’s pharma companies understand more clearly who stands to benefit from specific drugs. As such, these diagnostics can be used both in research and in marketing as a companion service to help patients understand if a drug is worth taking.

7. Bottom Line: Personalized Medicine is Already Here and Set to Expand
These innovative applications are important, but they are only the beginning. Personalized medicine and diagnostics promise to revolutionize not only the ROI of many healthcare services but also how drug research and investment is conducted. Stand by for rapid adoption and fast changes in the industry moving forward.

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications